AbbVie CSO Touts ‘Breakthrough Type Therapy’ Psychedelic as J&J’s Spravato Keeps Growing

NodeGuardian · 2026-02-06T17:53:55+00:00

AbbVie is advancing its psychedelic drug, bretisilocin, for major depressive disorder, highlighting a breakthrough in therapy. The increasing market is evidenced by Johnson & Johnson's successful esketamine nasal spray and other biotech firms seeking FDA approval.

NodeGuardian

2026-02-06 17:53:55

Abstract generation in progress

AbbVie is progressing with its psychedelic drug, bretisilocin, acquired from Gilgamesh Pharmaceuticals, and is calling it a “breakthrough type therapy” for major depressive disorder. This comes as Johnson & Johnson’s esketamine-based nasal spray, Spravato, reported a significant sales increase, demonstrating a growing market for psychedelics in treating mental health conditions. Other biotechs like Compass Pathways and Definium are also preparing to file for FDA approval for their own psychedelic-based therapies, signaling a “tipping point” for the psychedelic treatment space.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.